Pioneering Genetic Epidemiologist Takes a Global Approach to Fighting Health Disparities
Wednesday, June 16, 2021
IRP distinguished investigator Charles Rotimi, Ph.D., was elected to the American Academy of Arts and Sciences this year in recognition of his pioneering work exploring the health implications of genetic diversity in populations with African ancestry, as well as for globalizing the study of genomics, particularly in African nations. Dr. Rotimi joined NIH in 2008 as the founding director of the Intramural Center for Genomics and Health Disparities in the National Human Genome Research Institute (NHGRI), which was later renamed the Center for Research on Genomics and Global Health, in part to reflect Dr. Rotimi’s globe-spanning research programs.
NIH Researcher Recognized for Contributions to Structural Biology Techniques
Tuesday, January 19, 2021
The National Academy of Sciences (NAS), established in 1863, is comprised of the United States’ most distinguished scientific scholars, including nearly 500 Nobel Prize winners. Members of the NAS are elected by their peers and entrusted with the responsibility of providing independent, objective advice on national matters related to science and technology in an effort to advance innovations in the United States.
IRP senior investigator Robert Tycko, Ph.D., was one of two NIH researchers elected to the NAS in 2020, an honor he hopes will give him the opportunity to help other scientists and improve the way science is done.
Program Gives Boost to Early Stage Investigators
Monday, December 14, 2020
If TV shows like The Voice and America’s Got Talent are any indication, there are many extremely talented people out there who could become huge successes if presented with the right opportunity. This is no less the case in science, with thousands of extremely bright individuals quietly toiling away in their mentors’ labs as they await the chance to establish research programs of their own.
Fortunately, initiatives like the NIH’s Lasker Clinical Research Scholars Program exist to boost promising young researchers on to the next stage of their careers. Every year, the Lasker program allows a small group of early stage physician-scientists to establish their own labs at the NIH and carry out independent clinical research there for at least five years.
The five talented investigators selected as 2020 Lasker Scholars are pursuing a wide range of research questions, from how the immune system influences blood clotting to the mechanisms driving a rare and devastating skeletal disorder. Read on to learn more about the latest crop of researchers ramping up IRP labs of their very own.
Sugar Molecule Protects Mice Against Type 1 Diabetes
Monday, November 23, 2020
Avoiding too much sugar is one of the cardinal rules for those who have or are at risk for diabetes. In fact, diabetes is characterized by having too much glucose, a form of sugar, in the blood. As a result, it came as quite a surprise to IRP researchers led by senior investigator Wanjun Chen, M.D., when they discovered that a particular form of sugar that they expected to have no effect on diabetes-prone mice actually protected them from developing type 1 diabetes.
Hundreds of Young Researchers Present Their Work Online
Wednesday, May 6, 2020
The COVID-19 pandemic has dramatically altered the way scientists are doing their work. Nevertheless, scientific research is a highly collaborative and interactive enterprise, so it remains essential for researchers to share and discuss their ideas and discoveries.
Every spring, the NIH’s Postbac Poster Day offers recent college graduates participating in the NIH’s Postbaccalaureate IRTA program the chance to show off the fruits of their labors and talk about their projects with both their fellow postbacs and the NIH’s many seasoned scientific veterans. Due to the need to maintain social distancing, the NIH's Office of Intramural Training and Education (OITE) went through considerable effort to move this year’s Postbac Poster Day to an online forum. The OITE staff's hard work paid off handsomely, with more than 870 postbacs presenting their research via WebEx on April 28, 29, and 30. Keep reading for a few examples of the fascinating scientific questions NIH’s latest crop of postbacs has been investigating.
Study Suggests New Treatment Strategy for Increasingly Common Disease
Monday, April 6, 2020
In the classic sci-fi film Alien, the protagonist attempts to destroy the titular monster by triggering the self-destruct mechanism on her spaceship. Our cells also sometimes need to destroy themselves in order to circumvent threats like cancer, but uncontrolled cell death can lead to disease. New IRP research suggests that preventing certain cells in the pancreas from tripping their self-destruct switch could help relieve the symptoms of type 2 diabetes.
Exceptional Early-Stage Investigators Push the Boundaries of Translational Research
Thursday, December 5, 2019
Online and print publications are constantly touting momentous discoveries by superstar scientists like CRISPR-Cas9 co-discover Jennifer Doudna or the IRP’s own Kevin Hall, who changed the way we think about weight loss. It can be easy to forget that today’s biomedical pioneers were once young researchers toiling to establish themselves in the competitive environment of modern science.
Each year, a small, exceptionally promising group of scientific up-and-comers become Lasker Clinical Research Scholars through a highly competitive program jointly funded by the NIH and the Albert and Mary Lasker Foundation. The program presents early-stage physician-scientists with the opportunity to carry out independent clinical research at the NIH for five to ten years. The 2019 class of Lasker Scholars consists of five extremely talented researchers who are now beginning a critical new phase in their careers. Let’s meet them.
Therapeutic Strategy Enhances Natural Blood Sugar Control
Tuesday, October 1, 2019
Just like Sonny needed Cher to achieve music super-stardom and Stephen Curry needed Kevin Durant to win back-to-back NBA championships, sometimes a cell or molecule in the human body needs a partner’s assistance to work optimally. IRP researchers recently showed that a synergy between a lab-designed drug and a molecule naturally produced in the body could make for a promising therapy for type 2 diabetes.
Tuesday, December 11, 2018
The more scientists have learned about the community of benign bacteria inside our bodies, known as the microbiome, the more effort they have put into recruiting it in the fight against disease. What’s more, scientists occasionally discover that treatments long thought to work completely independently of our native microbes also relieve symptoms by interacting with them. New IRP research into the most commonly used medication for type 2 diabetes has led to just such a revelation by demonstrating that its benefits stem in part from its ability to kill off a particular species of bacteria in the human digestive tract.
Monday, May 7, 2018
On Wednesday, May 2, hundreds of researchers gathered at NIH’s Natcher Conference Center to show off their recent discoveries. But unlike a typical scientific conference, the letters “M.D.” and “Ph.D.” were noticeably absent from these scientists’ credentials. Instead, the event — NIH’s annual Postbac Poster Day — celebrated the accomplishments of individuals participating in the NIH Postbaccalaureate Intramural Research Training Award (IRTA) Program.